Viridian reports Q2 net loss of $127M; Lumvoa FDA-approved and launched in June

Viridian Therapeutics, Inc.\DE

Lumvoa (veligrotug-vvze) approved by FDA for thyroid eye disease on June 26, 2026, and immediately launched in U.S.
Elegrobart BLA submission on track for Q1 2027; phase 3 trials showed robust proptosis reduction.
Cash, cash equivalents, and marketable securities of $981.5M as of June 30, 2026, up from $762.2M at March 31, 2026.
Net loss for Q2 2026 was $127.1M, compared to $100.7M in Q2 2025; R&D expenses decreased to $71.6M from $86.6M.
Completed convertible debt and equity financing in May 2026 with gross proceeds of $394M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.